The European Medicines Agency (EMA) announced today that its Paediatric Committee (PDCO) will review drug developers' compliance with requirements to test medicines in children, intensifying oversight of paediatric investigation plans (PIPs). The review, published on 21 April 2026, aims to ensure that pharmaceutical companies adhere to mandatory testing obligations under EU paediatric regulation, potentially leading to enforcement actions for non-compliance.
Document details and purpose The announcement, issued by the EMA's Human Medicines Division, is a formal notice of a compliance review. It follows the Agency's 16 April 2026 introduction of a standardised PIP submission form, which replaced the previous free-text format to reduce administrative burden and improve consistency. The new review process builds on that standardisation by actively monitoring whether developers meet their commitments.
Policy orientations and trade-offs The EMA's move strengthens enforcement of paediatric testing rules, which require companies to submit PIPs early in drug development. This increases regulatory pressure on pharmaceutical firms, potentially accelerating availability of age-appropriate medicines for children. However, it may also raise development costs and delay market entry for some drugs, as companies must allocate resources to paediatric trials that may have limited commercial return.
Impact on stakeholders - Pharmaceutical companies: Face tighter compliance scrutiny and potential penalties for failing to conduct paediatric studies. This could increase R&D costs and slow time-to-market for new drugs. - Children and paediatric patients: Stand to benefit from improved access to medicines tested and tailored for their age group, addressing a long-standing gap in drug development. - EMA and national competent authorities: Gain enhanced oversight tools to enforce paediatric regulation, reinforcing the EU's commitment to child health. - Healthcare providers: May receive better data on paediatric dosing and safety, improving prescribing confidence.
Expected institutional follow-up The PDCO will conduct the review and may issue warnings, fines, or require revised PIPs from non-compliant developers. The EMA is expected to report findings later in 2026, potentially leading to further regulatory guidance or legislative proposals to strengthen paediatric drug development.
← Atlas › News › Health & Lifestyle